{"id":"faslodex-dummy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Hot flashes"},{"rate":"20-40%","effect":"Musculoskeletal pain"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By degrading estrogen receptors, Faslodex prevents estrogen from binding and promoting the growth of breast cancer cells. This mechanism is particularly effective in treating hormone receptor-positive breast cancer.","oneSentence":"Faslodex is a selective estrogen receptor degrader (SERD) that blocks estrogen receptors in breast cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:21.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, hormone receptor-positive"},{"name":"Locally advanced or metastatic breast cancer, hormone receptor-positive"}]},"trialDetails":[{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT00327769","phase":"PHASE3","title":"Faslodex Advanced Breast Cancer Local Chinese Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Advanced Breast Cancer","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"faslodex dummy","genericName":"faslodex dummy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Faslodex is a selective estrogen receptor degrader (SERD) that blocks estrogen receptors in breast cancer cells. Used for Metastatic breast cancer, hormone receptor-positive, Locally advanced or metastatic breast cancer, hormone receptor-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}